HIGHLIGHTS
- who: Aspirin Clopidogrel Ticagrelor et al. from the Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands Department of Cardiology, Radboud University Medical have published the research: P2Y12 blocker monotherapy after percutaneous coronary intervention, in the Journal: (JOURNAL)
- what: This short review will address the safety and efficacy of a reduction in DAPT-related bleeding by discontinuing aspirin rather than the P2Y12 blocker at the time of DAPT cessation, as has recently been evaluated in large-scale randomised clinical trials.
SUMMARY
Whether patients on ticagrelor monotherapy benefit more than those . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.